Prognosis in patients with atrial fibrillation and a presumed “temporary cause” in a community-based cohort study

Clinical Research in Cardiology

Volumn 106, Issue 3, 2017, Pages 202-210

  Fauchier, Laurent ^a   Clementy, Nicolas ^a   Bisson, Arnaud ^a   Stamboul, Karim ^b   Ivanes, Fabrice ^a   Angoulvant, Denis ^a   Babuty, Dominique ^a   Lip, Gregory Y H ^c,d  

^a SERVICE DE DERMATOLOGIE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; Oral anticoagulant; Stroke

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ALCOHOL CONSUMPTION; ARTICLE; ATRIAL FIBRILLATION; ATRIOVENTRICULAR CONDUCTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ELECTROCARDIOGRAM; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPERTHYROIDISM; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOCARDITIS; PAROXYSMAL ATRIAL FIBRILLATION; PERCUTANEOUS CORONARY INTERVENTION; PERICARDITIS; PROGNOSIS; RISK ASSESSMENT; THYROID DISEASE; VASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; EUROPE; FOLLOW UP; INCIDENCE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; TIME FACTOR; TRENDS;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; TIME FACTORS;

EID: 84989179900     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-016-1040-7     Document Type: Article

References (31)

1. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867
2. Lip GYH, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272. doi:10.1378/chest.09-1584
3. Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747. doi:10.1093/eurheartj/ehs253
4. January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–76. doi:10.1016/j.jacc.2014.03.022
5. Walkey AJ, Hogarth DK, Lip GYH (2015) Optimizing atrial fibrillation management: from ICU and beyond. Chest 148:859–864. doi:10.1378/chest.15-0358
6. Banerjee A, Fauchier L, Vourc’h P et al (2013) Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 61:2079–2087. doi:10.1016/j.jacc.2013.02.035
7. Philippart R, Brunet-Bernard A, Clementy N et al (2015) Prognostic value of CHA2DS2-VASc score in patients with “non-valvular atrial fibrillation” and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 36:1822–1830. doi:10.1093/eurheartj/ehv163
8. Fauchier L, Lecoq C, Clementy N et al (2015) Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project. Chest. doi:10.1378/chest.15-1622
9. Gage BF, Yan Y, Milligan PE et al (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151:713–719. doi:10.1016/j.ahj.2005.04.017
10. Lip GYH, Andreotti F, Fauchier L et al (2011) Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 106:997–1011. doi:10.1160/TH11-10-0690
11. Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351. doi:10.1161/CIRCULATIONAHA.106.685313
12. Stamboul K, Zeller M, Fauchier L et al (2015) Prognosis of silent atrial fibrillation after acute myocardial infarction at 1-year follow-up. Heart Br Card Soc 101:864–869. doi:10.1136/heartjnl-2014-307253
13. Annane D, Sébille V, Duboc D et al (2008) Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med 178:20–25. doi:10.1164/rccm.200701-031OC
14. Salman S, Bajwa A, Gajic O, Afessa B (2008) Paroxysmal atrial fibrillation in critically ill patients with sepsis. J Intensive Care Med 23:178–183. doi:10.1177/0885066608315838
15. Walkey AJ, Wiener RS, Ghobrial JM et al (2011) Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 306:2248–2254. doi:10.1001/jama.2011.1615
16. Goette A, Nattel S, Kalman J et al (2016) EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. doi:10.1093/europace/euw161
17. Bukowska A, Zacharias I, Weinert S et al (2013) Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Eur J Pharmacol 718:114–123. doi:10.1016/j.ejphar.2013.09.006
18. Page RL, Wilkinson WE, Clair WK et al (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89:224–227
19. Potpara TS, Polovina MM, Marinkovic JM, Lip GYH (2013) A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 168:4744–4749. doi:10.1016/j.ijcard.2013.07.234
20. Martinez C, Katholing A, Freedman SB (2014) Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost 112:276–286. doi:10.1160/TH4-04-0383
21. Lip GYH, Skjøth F, Nielsen PB, Larsen TB (2015) Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 114:826–834. doi:10.1160/TH15-07-0565
22. Champion S, Lefort Y, Gaüzère B-A et al (2014) CHADS2 and CHA2DS2-VASc scores can predict thromboembolic events after supraventricular arrhythmia in the critically ill patients. J Crit Care 29:854–858. doi:10.1016/j.jcrc.2014.05.010
23. Sibley S, Muscedere J (2015) New-onset atrial fibrillation in critically ill patients. Can Respir J J Can Thorac Soc 22:179–182
24. Labbé V, Ederhy S, Fartoukh M, Cohen A (2015) Should we administrate anticoagulants to critically ill patients with new onset supraventricular arrhythmias? Arch Cardiovasc Dis 108:217–219. doi:10.1016/j.acvd.2015.01.001
25. Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962. doi:10.1016/S0140-6736(13)62343-0
26. Caldeira D, Costa J, Ferreira JJ et al (2015) Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol Off J Ger Card Soc 104:582–590. doi:10.1007/s00392-015-0821-8
27. Nielsen PB, Lane DA, Rasmussen LH et al (2015) Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol Off J Ger Card Soc 104:418–429. doi:10.1007/s00392-014-0797-9
28. Gorin L, Fauchier L, Nonin E et al (2011) Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 140:911–917. doi:10.1378/chest.10-2436
29. Association European Heart Rhythm, Association European, for Cardio-Thoracic Surgery, Camm AJ et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 12:1360–1420. doi:10.1093/europace/euq350
30. Sabouret P, Depret-Bixio L, Cotte F-E et al (2014) Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database. Clin Res Cardiol Off J Ger Card Soc 103:887–893. doi:10.1007/s00392-014-0726-y
31. Skeppholm M, Friberg L (2014) Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol Off J Ger Card Soc 103:998–1005. doi:10.1007/s00392-014-0742-y